Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E

Youngseok Cho; Eun Sol Ha; In Hwan Baek; Min Soo Kim; Cheong Weon Cho; Sung Joo Hwang

doi:10.3390/molecules20069496

Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E

Youngseok Cho, Eun Sol Ha, In Hwan Baek, Min Soo Kim, Cheong Weon Cho, Sung Joo Hwang

Department of Pharmacy

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability. Sirolimus-loaded solid dispersions were fabricated by a spray drying process. A kinetic solubility test demonstrated that the sirolimus/E-SD/TPGS (1/8/1) solid dispersion had a maximum solubility of 196.7 μg/mL within 0.5 h that gradually decreased to 173.4 μg/mL after 12 h. According to the dissolution study, the most suitable formulation was the sirolimus/E-SD/TPGS (1/8/1) solid dispersion in simulated gastric fluid (pH 1.2), owing to enhanced stability and degree of supersaturation of E-SD and TPGS. Furthermore, pharmacokinetic studies in rats indicated that compared to the physical mixture and sirolimus/HPMC/TPGS (1/8/1) solid dispersion, the sirolimus/E-SD/TPGS (1/8/1) solid dispersion significantly improved oral absorption of sirolimus. E-SD significantly inhibited the degradation of sirolimus in a dose-dependent manner. E-SD also significantly inhibited the precipitation of sirolimus compared to hydroxypropylmethyl cellulose (HPMC). Therefore, the results from the present study suggest that the sirolimus-loaded E-SD/TPGS solid dispersion has great potential in clinical applications.

Original language	English
Pages (from-to)	9496-9509
Number of pages	14
Journal	Molecules
Volume	20
Issue number	6
DOIs	https://doi.org/10.3390/molecules20069496
Publication status	Published - 2015 Jun 1

All Science Journal Classification (ASJC) codes

Analytical Chemistry
Chemistry (miscellaneous)
Molecular Medicine
Pharmaceutical Science
Drug Discovery
Physical and Theoretical Chemistry
Organic Chemistry

Access to Document

10.3390/molecules20069496

Fingerprint Dive into the research topics of 'Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E'. Together they form a unique fingerprint.

Cite this

@article{576f911b109d4d9685ca703139fd39bb,

title = "Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit{\textregistered} E",

abstract = "The present study aimed to investigate the effect of Eudragit{\textregistered} E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability. Sirolimus-loaded solid dispersions were fabricated by a spray drying process. A kinetic solubility test demonstrated that the sirolimus/E-SD/TPGS (1/8/1) solid dispersion had a maximum solubility of 196.7 μg/mL within 0.5 h that gradually decreased to 173.4 μg/mL after 12 h. According to the dissolution study, the most suitable formulation was the sirolimus/E-SD/TPGS (1/8/1) solid dispersion in simulated gastric fluid (pH 1.2), owing to enhanced stability and degree of supersaturation of E-SD and TPGS. Furthermore, pharmacokinetic studies in rats indicated that compared to the physical mixture and sirolimus/HPMC/TPGS (1/8/1) solid dispersion, the sirolimus/E-SD/TPGS (1/8/1) solid dispersion significantly improved oral absorption of sirolimus. E-SD significantly inhibited the degradation of sirolimus in a dose-dependent manner. E-SD also significantly inhibited the precipitation of sirolimus compared to hydroxypropylmethyl cellulose (HPMC). Therefore, the results from the present study suggest that the sirolimus-loaded E-SD/TPGS solid dispersion has great potential in clinical applications.",

author = "Youngseok Cho and Ha, {Eun Sol} and Baek, {In Hwan} and Kim, {Min Soo} and Cho, {Cheong Weon} and Hwang, {Sung Joo}",

year = "2015",

month = jun,

day = "1",

doi = "10.3390/molecules20069496",

language = "English",

volume = "20",

pages = "9496--9509",

journal = "Molecules",

issn = "1420-3049",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® E

AU - Cho, Youngseok

AU - Ha, Eun Sol

AU - Baek, In Hwan

AU - Kim, Min Soo

AU - Cho, Cheong Weon

AU - Hwang, Sung Joo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability. Sirolimus-loaded solid dispersions were fabricated by a spray drying process. A kinetic solubility test demonstrated that the sirolimus/E-SD/TPGS (1/8/1) solid dispersion had a maximum solubility of 196.7 μg/mL within 0.5 h that gradually decreased to 173.4 μg/mL after 12 h. According to the dissolution study, the most suitable formulation was the sirolimus/E-SD/TPGS (1/8/1) solid dispersion in simulated gastric fluid (pH 1.2), owing to enhanced stability and degree of supersaturation of E-SD and TPGS. Furthermore, pharmacokinetic studies in rats indicated that compared to the physical mixture and sirolimus/HPMC/TPGS (1/8/1) solid dispersion, the sirolimus/E-SD/TPGS (1/8/1) solid dispersion significantly improved oral absorption of sirolimus. E-SD significantly inhibited the degradation of sirolimus in a dose-dependent manner. E-SD also significantly inhibited the precipitation of sirolimus compared to hydroxypropylmethyl cellulose (HPMC). Therefore, the results from the present study suggest that the sirolimus-loaded E-SD/TPGS solid dispersion has great potential in clinical applications.

AB - The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral bioavailability. Sirolimus-loaded solid dispersions were fabricated by a spray drying process. A kinetic solubility test demonstrated that the sirolimus/E-SD/TPGS (1/8/1) solid dispersion had a maximum solubility of 196.7 μg/mL within 0.5 h that gradually decreased to 173.4 μg/mL after 12 h. According to the dissolution study, the most suitable formulation was the sirolimus/E-SD/TPGS (1/8/1) solid dispersion in simulated gastric fluid (pH 1.2), owing to enhanced stability and degree of supersaturation of E-SD and TPGS. Furthermore, pharmacokinetic studies in rats indicated that compared to the physical mixture and sirolimus/HPMC/TPGS (1/8/1) solid dispersion, the sirolimus/E-SD/TPGS (1/8/1) solid dispersion significantly improved oral absorption of sirolimus. E-SD significantly inhibited the degradation of sirolimus in a dose-dependent manner. E-SD also significantly inhibited the precipitation of sirolimus compared to hydroxypropylmethyl cellulose (HPMC). Therefore, the results from the present study suggest that the sirolimus-loaded E-SD/TPGS solid dispersion has great potential in clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=84938220022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938220022&partnerID=8YFLogxK

U2 - 10.3390/molecules20069496

DO - 10.3390/molecules20069496

M3 - Article

C2 - 26020699

AN - SCOPUS:84938220022

VL - 20

SP - 9496

EP - 9509

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 6

ER -